Biotech & MedTech News
-
DIAGNOS Announces Closing of First Tranche of Private Placement
February 27, 2024 (Source) — DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer…
-
FendX and Dunmore Continue Successful Collaboration to Further REPELWRAP(TM) Film Development with a Next Pilot Manufacturing Run
February 27, 2024 (Source) — FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the “Company” or “FendX”) a nanotechnology…
-
Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK
Exclusive rights to universal CAR technology platform designed to target multiple antigens simultaneously, recently expanded to include SNAP-CAR…
-
Diagnos Announces Variation in One Insider Ownership of Common Shares
February 23, 2024 (Source) — In accordance with regulatory requirements, Diagnos Inc. (“DIAGNOS”, the “Corporation” or the “Issuer”)…
-
DIAGNOS recognized as a Top TSX Venture Exchange Company
February 21, 2024 (Source) — DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer…
-
FendX Completes Third Pilot Run to Manufacture REPELWRAP(TM) Film using Dunmore’s Commercial Equipment
February 13, 2024 (Source) — FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the “Company” or “FendX”), a nanotechnology…
-
Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections
Novel NK cell therapy approach is designed to bolster and replenish the immune system during severe viral infection, which…
-
Hemostemix Announces Updated Phase II Randomized Clinical Trial Results Published by the Journal of Biomedical Research and Environmental Sciences
February 6, 2024 (Source) — Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company”) is…
-
FendX Technologies Announces Closing of Non-Brokered Private Placement with Strategic Investors and Upsizing
February 2, 2024 (Source) — FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the “Company” or “FendX”) a nanotechnology…
-
Zentek Announces Positive Therapeutic Results achieved by Triera Biosciences for C19HBA
January 30, 2024 (Source) — Zentek Ltd. (“Zentek” or the “Company”) (Nasdaq:ZTEK)(TSX-V:ZEN) announces that its wholly-owned subsidiary Triera Biosciences…
